DTX3L and diffuse large B-cell lymphoma: Taken together, DTX3L might serve as a novel useful prognostic biomarker for poor survival and as a rational drug target for treatment of high-risk relapsed/refractory HR- (and BCR-) subtypes of DLBCL-NOS.